Hoth Therapeutics, Inc., was incorporated under the laws of the State of Nevada on May 16, 2017. The company is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for unmet medical needs. Its R&D pipeline includes drug candidates for tumor treatment-related side effects, mast cell-derived cancers, neuroinflammatory diseases and other indications.
